Skip to main content
Back to timeline
Venture CapitalSource publication:

MegaRobo raises nearly US$200 million: wiring AI agents into real lab benches, with wet-lab validation for over 10,000 protein designs

Synopsis

MegaRobo announced a new financing round of nearly US$200 million, joined by Oman Investment Authority, with existing investors Asia Investment Capital, Granite Asia and Sinovation Ventures continuing to back the company and CMB International joining as a new participant. The funds will support core technology, global expansion of its AI for Science business, and infrastructure that lets AI operate in increasingly complex physical environments. The company says its One Intelligence Stack combines models and agents, data, workflows, software, scientific instruments, robotics, automation and real-world feedback into one reusable technology foundation, and that it has delivered products and technologies to more than 500 customers.

AI-generated editorial illustration: MegaRobo Raises Nearly US$200 Million in New Funding to Build Intelligence Infrastructure for the Physical World

Interpretation

MegaRobo raised nearly US$200 million in a new round to fund core technology, global expansion of its AI for Science business, and infrastructure for AI operating in more complex physical environments. The company had previously raised approximately US$600 million across multiple rounds, including a nearly US$300 million Series C co-led by Goldman Sachs Alternatives, Asia Investment Capital and Granite Asia, with participation from Pavilion Capital, part of Temasek's Seviora Group. Oman Investment Authority joined this round, existing investors Asia Investment Capital, Granite Asia and Sinovation Ventures continued to back the company, and CMB International participated as a new investor.

The company treats scientific discovery and pharmaceutical R&D as the first proving ground for this architecture, covering stages from early research and target and mechanism discovery to drug screening and candidate optimization. The company says its products and technologies have been delivered to more than 500 customers, including global pharmaceutical companies, drug discovery organizations, biotechnology companies and research institutions. Megalaxy Lab lets researchers and AI agents configure experiments, route them to automated laboratory systems, track execution and receive structured, machine-readable results; the platform has served more than 200 customers.

With industry partners including Tencent Cloud and Twist Bioscience, MegaRobo launched Poreva Open, a global AI protein design challenge open to all models and technical approaches. Megalaxy Lab will provide wet-lab validation for more than 10,000 protein design sequences, letting researchers worldwide test their models against real experimental results. The challenge aims to establish a common benchmark for AI-driven protein design by opening large-scale experimental validation to the global research community.

Perspective

The report covers the announced round, the existing product and customer scale, and the Poreva Open plan; it is aimed at researchers and engineers following AI for Science infrastructure and automated experimentation.

The round is described as nearly US$200 million, and the customer counts and validation scale are company figures; results of the Poreva Open validation and the resulting benchmark have not been published.